Andreas Hombach
Overview
Explore the profile of Andreas Hombach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
673
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hombach A, Barden M, Hannappel L, Chmielewski M, Rappl G, Sachinidis A, et al.
Mol Ther
. 2021 Oct;
30(2):593-605.
PMID: 34678512
Chimeric antigen receptor (CAR)-redirected T cell therapy often fails to control tumors in the long term due to selecting cancer cells that downregulated or lost CAR targeted antigen. To reprogram...
2.
Ambrose C, Su L, Wu L, Dufort F, Sanford T, Birt A, et al.
PLoS One
. 2021 Mar;
16(3):e0247701.
PMID: 33735268
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we...
3.
Patasic L, Seifried J, Bezler V, Kaljanac M, Schneider I, Schmitz H, et al.
Med Microbiol Immunol
. 2020 Sep;
209(6):681-691.
PMID: 32918599
Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers...
4.
Aleksandrova K, Leise J, Priesner C, Melk A, Kubaink F, Abken H, et al.
Transfus Med Hemother
. 2019 Jun;
46(1):47-54.
PMID: 31244581
Clinical studies using autologous CAR T cells have achieved spectacular remissions in refractory CD19+ B cell leukaemia, however some of the patient treatments with CAR T cells failed. Beside the...
5.
Krug C, Birkholz K, Paulus A, Schwenkert M, Schmidt P, Hoffmann N, et al.
Cancer Immunol Immunother
. 2015 Oct;
64(12):1623-35.
PMID: 26515978
Chimeric antigen receptor (CAR)-modified T cells emerged as effective tools in the immunotherapy of cancer but can produce severe on-target off-tissue toxicities. This risk can conceivably be overcome, at least...
6.
Brinkmann K, Hombach A, Seeger J, Wagner-Stippich D, Klubertz D, Kronke M, et al.
Leuk Lymphoma
. 2013 May;
55(3):645-51.
PMID: 23697877
Resistance to apoptosis is a hallmark of cancer, and represents an important mechanism of how tumor cells resist immune cell destruction. Mitochondria are the central regulators of the apoptotic machinery...
7.
Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H
Proc Natl Acad Sci U S A
. 2011 Feb;
108(6):2474-9.
PMID: 21282657
Proceeding on the assumption that all cancer cells have equal malignant capacities, current regimens in cancer therapy attempt to eradicate all malignant cells of a tumor lesion. Using in vivo...
8.
Rappl G, Schrama D, Hombach A, Meuer E, Schmidt A, Becker J, et al.
Rejuvenation Res
. 2008 Jul;
11(3):543-56.
PMID: 18593274
CD7(-) T cells constitute a distinct subset within the CD4(+) and CD8(+) T cell populations; their developmental and functional relationship to the majority of CD7(+) T cells, however, remained so...
9.
Savoldo B, Rooney C, Di Stasi A, Abken H, Hombach A, Foster A, et al.
Blood
. 2007 May;
110(7):2620-30.
PMID: 17507664
Adoptive transfer of Epstein Barr virus (EBV)-specific cytotoxic T-lymphocytes (EBV-CTLs) has shown that these cells persist in patients with EBV(+) Hodgkin lymphoma (HD) to produce complete tumor responses. Treatment failure,...
10.
Koehler H, Kofler D, Hombach A, Abken H
Cancer Res
. 2007 Mar;
67(5):2265-73.
PMID: 17332357
The T-cell-mediated antitumor immune response is frequently repressed in the tumor environment by an immunologic barrier, the predominant mediators of which are thought to be interleukin-10 (IL-10) and transforming growth...